Salicylic acid with lactic acid
Brand names: Salactol, Cuplex, Duofilm
A topical keratolytic combination of salicylic acid and lactic acid, commonly formulated as a paint or collodion for the treatment of common and plantar warts and verrucae.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Both components are keratolytic: salicylic acid softens and desquamates hyperkeratotic skin by dissolving intercellular cement, while lactic acid (an alpha-hydroxy acid) further promotes shedding of the affected keratinocytes, gradually destroying the wart.
Prescribing in practice
- Apply only to the wart or verruca and protect surrounding healthy skin, as the keratolytic action can cause irritation, burning and ulceration of normal skin.
- Avoid use on the face, anogenital region and on broken or inflamed skin, and do not use on warts in patients with diabetes or peripheral vascular disease without specialist advice.
- The flammable collodion or paint base should be kept away from naked flames and allowed to dry before dressing.
Monitoring
No laboratory monitoring is required; review the treated lesion periodically for excessive irritation and response, abrading the softened keratin between applications.
Counselling the patient
- Soak the area in warm water and gently file down the softened skin before each application, applying the liquid only to the wart.
- Treatment often takes several weeks of regular use; persist but stop and seek advice if the skin becomes very sore or broken.
- Keep the product away from the eyes, mouth and flames as it is flammable.
Evidence & guidelines
Topical salicylic acid preparations are an established first-line self-care treatment for cutaneous warts, supported by Cochrane evidence showing modest benefit over placebo.
Reference: NICE CKS; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Tumor Lysis Syndrome Risk (Cairo-Bishop) · Oncological Emergency
- FAST Exam Protocol — Focused Assessment with Sonography in Trauma · Trauma
- Urine Anion Gap · Acid-Base
- Bicarbonate Deficit Calculator · Acid-Base
- Delta Ratio for Mixed Acid-Base Disorders · Acid-Base
- Expected PaCO₂ in Metabolic Acidosis (Winter's Formula) · Acid-Base
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD